Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL

Boegemann M, Bedke J, Schostak M, Welslau M, Hering-Schubert C, Wolf T, Schleicher J, Petzoldt A, Doehn C, Gruellich C, Gruenwald , Steiner T, Ehness R, Klein D, Medinger T, Goebell P (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 41

Pages Range: 201-202

DOI: 10.1200/jco.2018.36.15_suppl.4584

Authors with CRIS profile

Peter Goebell Urologische Klinik

Involved external institutions

iOMEDICO AG DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Otto-von-Guericke-Universität Magdeburg DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) HELIOS Kliniken DE Germany (DE) Urologikum Lübeck DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Novartis AG CH Switzerland (CH) Universitätsklinikum Jena DE Germany (DE) Klinikum Stuttgart DE Germany (DE)

How to cite

APA:

Boegemann, M., Bedke, J., Schostak, M., Welslau, M., Hering-Schubert, C., Wolf, T.,... Goebell, P. (2018). Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL. (pp. 201-202).

MLA:

Boegemann, M., et al. "Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL." 2018. 201-202.

BibTeX: Download